ABSTRACT
Our previous pre-clinical work defined BCL-2 induction as a critical component of the adaptive response to lapatinib-mediated inhibition of HER2. To determine whether a similar BCL-2 upregulation occurs in lapatinib-treated patients, we evaluated gene expression within tumor biopsies, collected before and after lapatinib or trastuzumab treatment, from the TRIO-B-07 clinical trial (NCT#00769470). We detected BCL-2 mRNA upregulation in both HER2+/ER- as well as HER2+/ER+ patient tumors treated with lapatinib or trastuzumab. To address whether mRNA expression correlated with protein expression, we evaluated pre- and post-treatment tumors for BCL-2 via immunohistochemistry. Despite BCL-2 mRNA upregulation within HER2+/ER- tumors, BCL-2 protein levels were undetectable in most of the lapatinib- or trastuzumab-treated HER2+/ER- tumors. BCL-2 upregulation was evident within the majority of lapatinib-treated HER2+/ER+ tumors and was often coupled with increased ER expression and decreased proliferation. Comparable BCL-2 upregulation was not observed within the trastuzumab-treated HER2+/ER+ tumors. Together, these results provide clinical validation of the BCL-2 induction associated with the adaptive response to lapatinib and support evaluation of BCL-2 inhibitors within the context of lapatinib and other HER2-targeted receptor tyrosine kinase inhibitors.
Competing Interest Statement
S.A. Hurvitz Contracted Research: Ambrx Amgen Astra Zeneca Arvinas Bayer Daiichi-Sankyo Genentech/Roche Gilead GSK Immunomedics Lilly Macrogenics Novartis Pfizer OBI Pharma Pieris PUMA Radius Sanofi Seattle Genetics Dignitana Zymeworks Phoenix Molecular Designs, Ltd. Stock Options: NK Max Travel: Lilly M.F. Press Consulting or Advisory Role: AstraZeneca Biocartis SA CEPHEID Clinical Care Options, LLC CME Outfitters, LLC Lilly USA, LLC Merck & Co. Puma Biotechnology Zymeworks Inc. Eli Lilly & Company Private Equity Role: TORL BIOTHERAPEUTICS LLC All other authors have declared that no competing interests exist.
Clinical Trial
NCT#00769470
Funding Statement
Our work was supported by a Department of Defense Breast Cancer Research Fellowship Award [https://cdmrp.army.mil/bcrp/], Award Number W81XWH-11-1-0572 (to J.J. Zoeller), a Breast Cancer Research Foundation Grant [https://www.bcrf.org] (to M.F. Press) and a Stand Up To Cancer-American Association for Cancer Research Dream Team Translational Cancer Research Grant [https://standuptocancer.org], Grant Number SU2C-AACR-DT0409 (to J.S. Brugge and D.J. Slamon). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Tumor biopsies were collected from patients enrolled in the TRIO-B-07 clinical trial (NCT#00769470) as previously described (Hurvitz 2020). TRIO-B-07 was reviewed and approved by multiple institutional review boards (UCLA; Olive View; Western), and all participants signed an IRB-approved informed consent form. The Institutional Review Board (IRB) of the Harvard University Faculty of Medicine reviewed and determined that our study is not human subjects research. Our UCLA Data Use Agreement (DUA) confirmed that all samples were de-identified and that access to identifiers (or links to identities) of individuals from whom the samples were collected would not be granted under any circumstances. Hurvitz SA, Caswell-Jin JL, McNamara KL, Zoeller JJ, Bean GR, Dichmann R, et al. Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07). Nature Communications. 2020;11(1):5824.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
jason_zoeller{at}hms.harvard.edu, press{at}usc.edu, laura_selfors{at}hms.harvard.edu, jdering001{at}roadrunner.com, dslamon{at}mednet.ucla.edu, shurvitz{at}mednet.ucla.edu, joan_brugge{at}hms.harvard.edu
Data Availability
The TRIO-B-07 data files are publicly available from the GEO database (GSE130788).
List of Abbreviations
- B×
- biopsy
- DUA
- Data Usage Agreement
- DF
- Dana-Farber
- GSE
- Gene Series Expression
- HCC
- Harvard Cancer Center
- HER2
- human epidermal growth factor receptor-2
- ER
- estrogen receptor
- FOXO
- members of the class O of forkhead box transcription factors
- H&E
- hematoxylin-and-eosin
- H-score
- histo-score
- IHC
- immunohistochemistry
- IRB
- institutional review board
- L
- lapatinib
- mTOR
- mammalian target of rapamycin
- NCT
- National Clinical Trial
- p
- p-value
- PI3K
- phosphoinositide 3-kinase
- r
- Spearman correlation
- RNA
- ribonucleic acid
- SAM
- Significance Analysis of Microarrays
- T
- trastuzumab
- T×
- treatment
- UCLA
- University of California Los Angeles
